Dendrimer-mediated approaches for the treatment of brain tumor

References

• WHO. New guide on palliative care services for people living with advanced cancer, http://www.who.int/mediacentre/news/notes/2007/np31/en/.
   Google Scholar
• Thakur S, Kesharwani P, Tekade RK, et al. Impact of pegylation on biopharmaceutical properties of dendrimers. Polymer. 2015;59:67–92.10.1016/j.polymer.2014.12.051
   Web of Science ®Google Scholar
• Kesharwani P, Mishra V, Jain NK. Validating the anticancer potential of carbon nanotube-based therapeutics through cell line testing. Drug Discovery Today. 2015;20:1049–1060.10.1016/j.drudis.2015.05.004
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Ghanghoria R, Jain NK. Carbon nanotube exploration in cancer cell lines. Drug Discovery Today. 2012;17:1023–1030.10.1016/j.drudis.2012.05.003
   PubMed Web of Science ®Google Scholar
• Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-Oncology. 2012;14(Suppl 5):v1–v49.10.1093/neuonc/nos218
   PubMed Web of Science ®Google Scholar
• Wen PY, Kesari S. Malignant gliomas in adults. N. Engl. J. Med. 2008;359:492–507.10.1056/NEJMra0708126
   PubMed Web of Science ®Google Scholar
• DeAngelis LM. Brain tumors. N. Engl. J. Med. 2001;344:114–123.10.1056/NEJM200101113440207
   PubMed Web of Science ®Google Scholar
• Scheithauer BW. Development of the WHO classification of tumors of the central nervous system: a historical perspective. Brain Pathol. 2009;19:551–564.10.1111/bpa.2009.19.issue-4
   PubMed Web of Science ®Google Scholar
• Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain. 2007;130:2596–2606.10.1093/brain/awm204
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352:987–996.10.1056/NEJMoa043330
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Iyer AK. Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery. Drug Discovery Today. 2015;20:536–547.10.1016/j.drudis.2014.12.012
   PubMed Web of Science ®Google Scholar
• Mubita L, Kalkanis SN. Chapter 7 – The role of chemotherapy in metastatic brain tumors. brain metastases from primary tumors, Epidemiology, Biology, and Therapy. 2014; 75–80. doi:10.1016/B978-0-12-800896-6.00007-3.
   Google Scholar
• Alam MI, Beg S, Samad A, et al. Strategy for effective brain drug delivery. Eur. J. Pharm. Sci. 2010;40:385–403.10.1016/j.ejps.2010.05.003
   PubMed Web of Science ®Google Scholar
• Juillerat-Jeanneret L. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discovery Today. 2008;13:1099–1106.10.1016/j.drudis.2008.09.005
   PubMed Web of Science ®Google Scholar
• Freitas RA. What is nanomedicine? Nanomed. Nanotechnol. Biol. Med. 2005;1:2–9.10.1016/j.nano.2004.11.003
   PubMed Web of Science ®Google Scholar
• Caruthers SD, Wickline SA, Lanza GM. Nanotechnological applications in medicine. Curr. Opin. Biotechnol. 2007;18:26–30.10.1016/j.copbio.2007.01.006
   PubMed Web of Science ®Google Scholar
• Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol. Pharm. 2011;8:2101–2141.10.1021/mp200394t
   PubMed Web of Science ®Google Scholar
• Jaracz S, Chen J, Kuznetsova LV, et al. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg. Med. Chem. 2005;13:5043–5054.10.1016/j.bmc.2005.04.084
   PubMed Web of Science ®Google Scholar
• Cheng Y, Morshed RA, Auffinger B, et al. Multifunctional nanoparticles for brain tumor imaging and therapy. Adv. Drug Delivery Rev. 2014;66:42–57.10.1016/j.addr.2013.09.006
   PubMed Web of Science ®Google Scholar
• Singh R, Kesharwani P, Mehra NK, et al. Development and characterization of folate anchored Saquinavir entrapped PLGA nanoparticles for anti-tumor activity. Drug Dev. Ind. Pharm. 2015;41:1888–1901.10.3109/03639045.2015.1019355
   PubMed Web of Science ®Google Scholar
• Kothule KU, Kesharwani P, Gidwani SK, et al. Development and characterization of chitosan nanoparticles and improvement of oral bioavailability of poorly water soluble acyclovir. Res. J. Pharm. Technol. 2010;3:1241–1245.
   Google Scholar
• Zucchetti M, Boiardi A, Silvani A, et al. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin. Cancer Chemother. Pharmacol. 1999;44:173–176.10.1007/s002800050964
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Aghajanian CA, Alberts DS, et al. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol. Oncol. 2005;96:10–18.10.1016/j.ygyno.2004.09.046
   PubMed Web of Science ®Google Scholar
• Dande P, Prakash TP, Sioufi N, et al. Improving RNA interference in mammalian cells by 4′-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2′-O-alkyl modifications. J. Med. Chem. 2006;49:1624–1634.10.1021/jm050822c
   PubMed Web of Science ®Google Scholar
• Tekade RK, Kumar PV, Jain NK. Dendrimers in oncology: an expanding horizon. Chem. Rev. 2009;109:49–87.10.1021/cr068212n
   PubMed Web of Science ®Google Scholar
• Akhter S, Ahmad I, Ahmad MZ, et al. Nanomedicines as cancer therapeutics: current status. Curr. Cancer Drug Targets 2013;13:362–378.10.2174/1568009611313040002
   PubMed Web of Science ®Google Scholar
• Mignani S, El Kazzouli S, Bousmina M, et al. Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: a concise overview. Adv. Drug Delivery Rev. 2013;65:1316–1330.10.1016/j.addr.2013.01.001
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Prog. Polym. Sci. 2014;39:268–307.10.1016/j.progpolymsci.2013.07.005
   Web of Science ®Google Scholar
• Kesharwani P, Tekade RK, Jain NK. Generation dependent cancer targeting potential of poly(propyleneimine) dendrimer. Biomaterials. 2014;35:5539–5548.10.1016/j.biomaterials.2014.03.064
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Tekade RK, Jain NK. Dendrimer generational nomenclature: the need to harmonize. Drug Discovery Today. 2015;20:497–499.10.1016/j.drudis.2014.12.015
   PubMed Web of Science ®Google Scholar
• Birdhariya B, Kesharwani P, Jain NK. Effect of surface capping on targeting potential of folate decorated poly (propylene imine) dendrimers. Drug Dev. Ind. Pharm. 2015;41:1393–1399.10.3109/03639045.2014.954584
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Mishra V, Jain NK. Generation dependent hemolytic profile of folate engineered poly(propyleneimine) dendrimer. J. Drug Delivery Sci. Technol. 2015;28:1–6.10.1016/j.jddst.2015.04.006
   Web of Science ®Google Scholar
• Kesharwani P, Tekade RK, Gajbhiye V, et al. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomed. Nanotechnol. Biol. Med. 2011;7:295–304.10.1016/j.nano.2010.10.010
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Gajbhiye V, Tekade RK, et al. Evaluation of dendrimer safety and efficacy through cell line studies. Curr. Drug Targets. 2011;12:1478–1497.10.2174/138945011796818135
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials. 2012;33:7138–7150.10.1016/j.biomaterials.2012.06.068
   PubMed Web of Science ®Google Scholar
• Ihre H, Padilla De Jesús OL, Fréchet JM. Fast and convenient divergent synthesis of aliphatic ester dendrimers by anhydride coupling. J. Am. Chem. Soc. 2001;123:5908–5917.10.1021/ja010524e
   PubMed Web of Science ®Google Scholar
• Malik N, Wiwattanapatapee R, Klopsch R,et al. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J. Controlled Release. 2000;65:133–148.10.1016/S0168-3659(99)00246-1
   PubMed Web of Science ®Google Scholar
• Jain K, Kesharwani P, Gupta U, et al. Dendrimer toxicity: let’s meet the challenge. Int. J. Pharm. 2010;394:122–142.10.1016/j.ijpharm.2010.04.027
   PubMed Web of Science ®Google Scholar
• Jain K, Kesharwani P, Gupta U, et al. A review of glycosylated carriers for drug delivery. Biomaterials. 2012;33:4166–4186.10.1016/j.biomaterials.2012.02.033
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Tekade RK, Jain NK. Generation dependent safety and efficacy of folic acid conjugated dendrimer based anticancer drug formulations. Pharm. Res. 2015;32:1438–1450.10.1007/s11095-014-1549-2
   PubMed Web of Science ®Google Scholar
• Kesharwani P. Effect of generation G on cancer targeting propensity of PPI dendrimer. LAP Lambert Academic Publishing; 2015, ISBN-13: 978-3-8443-9285-2.
   Google Scholar
• Kesharwani P. Relative study of cancer targeting potential of engineered dendrimer. LAP Lambert Academic Publishing; 2015, ISBN- 13: 978-3-659-51741-9.
   Google Scholar
• Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv. Drug Delivery Rev. 2005;57:2215–2237.10.1016/j.addr.2005.09.019
   PubMed Web of Science ®Google Scholar
• Fréchet JMJ, Hawker CJ, Gitsov I, et al. Dendrimers and hyperbranched polymers: two families of three-dimensional macromolecules with similar but clearly distinct properties. J. Macromol. Sci. Part A. 2006;33:1399–1425.
   Web of Science ®Google Scholar
• Ihre HR, Padilla De Jesús OL, Szoka FC, et al. Polyester dendritic systems for drug delivery applications: design, synthesis, and characterization. Bioconjugate Chem. 13:443–452.
   PubMed Web of Science ®Google Scholar
• Islam MT, Majoros IJ, Baker JR. HPLC analysis of PAMAM dendrimer based multifunctional devices. J. Chromatogr. B. 2005;822:21–26.10.1016/j.jchromb.2005.05.001
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Xie L, Banerjee S, et al. Hyaluronic acid-conjugated polyamidoamine dendrimers for targeted delivery of 3,4-difluorobenzylidene curcumin to CD44 overexpressing pancreatic cancer cells. Colloids Surf. B. 2015;136:413–423.10.1016/j.colsurfb.2015.09.043
   PubMed Web of Science ®Google Scholar
• de Brabander-van den Berg EMM, Meijer EW. Poly(propylene imine) dendrimers: large-scale synthesis by hetereogeneously catalyzed hydrogenations. Angew. Chemie. Int. Ed. English. 1993;32:1308–1311.
   Web of Science ®Google Scholar
• Biricova V, Laznickova A. Dendrimers: analytical characterization and applications. Bioorg. Chem. 2009;37:185–192.10.1016/j.bioorg.2009.07.006
   PubMed Web of Science ®Google Scholar
• Caminade A, Laurent R, Majoral J. Characterization of dendrimers. Adv. Drug Delivery Rev.. 2005;57:2130–2146.10.1016/j.addr.2005.09.011
   PubMed Web of Science ®Google Scholar
• Li J, Piehler LT, Qin D, et al. Visualization and characterization of poly(amidoamine) dendrimers by atomic force microscopy. Langmuir. 2000;16:5613–5616.10.1021/la000035c
   Web of Science ®Google Scholar
• Stöckigt D, Lohmer G, Belder D. Separation and identification of basic dendrimers using capillary electrophoresis on-line coupled to a sector mass spectrometer. Rapid Commun. Mass Spectrom. 1996;10:521–526.10.1002/(ISSN)1097-0231
   Web of Science ®Google Scholar
• Nourse A, Millar DB, Minton AP. Physicochemical characterization of generation 5 polyamidoamine dendrimers. Biopolymers. 2000;53:316–328.10.1002/(ISSN)1097-0282
   PubMed Web of Science ®Google Scholar
• Gajbhiye V, Vijayaraj Kumar P, Tekade RK, et al. PEGylated PPI dendritic architectures for sustained delivery of H2 receptor antagonist. Eur. J. Med. Chem. 2009;44:1155–1166.10.1016/j.ejmech.2008.06.012
   PubMed Web of Science ®Google Scholar
• Wolinsky JB, Grinstaff MW. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv. Drug Delivery Rev. 2008;60:1037–1055.10.1016/j.addr.2008.02.012
   PubMed Web of Science ®Google Scholar
• Malik N, Evagorou EG, Duncan R. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs. 1999;10:767–776.10.1097/00001813-199909000-00010
   PubMed Web of Science ®Google Scholar
• Kojima C, Kono K, Maruyama K, et al. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjugate Chem. 11:910–917.
   PubMed Web of Science ®Google Scholar
• Bhadra D, Bhadra S, Jain S, et al. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int. J. Pharm. 2003;257:111–124.10.1016/S0378-5173(03)00132-7
   PubMed Web of Science ®Google Scholar
• Ooya T, Lee J, Park K. Hydrotropic dendrimers of generations 4 and 5: synthesis, characterization, and hydrotropic solubilization of paclitaxel. Bioconjugate Chem. 15:1221–1229
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Tekade RK, Jain NK. Formulation development and in vitro–in vivo assessment of the fourth-generation PPI dendrimer as a cancer-targeting vector. Nanomedicine. 2014;9:2291–2308.10.2217/nnm.13.210
   PubMed Web of Science ®Google Scholar
• Kannan RM, Nance E, Kannan S, et al. Emerging concepts in dendrimer-based nanomedicine: from design principles to clinical applications. J. Intern. Med. 2014;276:579–617.10.1111/joim.2014.276.issue-6
   PubMed Web of Science ®Google Scholar
• Iyer AK, Duan Z, Amiji MM. Nanodelivery systems for nucleic acid therapeutics in drug resistant tumors. Mol. Pharm. 2014;11:2511–2526.10.1021/mp500024p
   PubMed Web of Science ®Google Scholar
• Iyer AK, Khaled G, Fang J, et al. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discovery Today. 2006;11:812–818.10.1016/j.drudis.2006.07.005
   PubMed Web of Science ®Google Scholar
• Islam T, Josephson L. Current state and future applications of active targeting in malignancies using superparamagnetic iron oxide nanoparticles. Cancer Biomark. 2009;5:99–107.
   PubMed Web of Science ®Google Scholar
• Teow Y, Valiyaveettil S. Active targeting of cancer cells using folic acid-conjugated platinum nanoparticles. Nanoscale. 2010;2:2607–2613.10.1039/c0nr00204f
   PubMed Web of Science ®Google Scholar
• Thakur S, Tekade RK, Kesharwani P, et al. The effect of polyethylene glycol spacer chain length on the tumor-targeting potential of folate-modified PPI dendrimers. J. Nanopart. Res. 2013;15:1625. doi:10.1007/s11051-013-1625-210.1007/s11051-013-1625-2
   Web of Science ®Google Scholar
• Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs. 1992;3:175–210.10.1097/00001813-199206000-00001
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387–6392.
   PubMed Web of Science ®Google Scholar
• Padilla De Jesús OL, Ihre HR, Gagne L, et al. Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. Bioconjugate Chem. 13:453–461.
   PubMed Web of Science ®Google Scholar
• Gillies ER, Frechet JMJ. Dendrimers and dendritic polymers in drug delivery. Drug Discovery Today. 2005;10:35–43.10.1016/S1359-6446(04)03276-3
   PubMed Web of Science ®Google Scholar
• Greish K, Fang J, Inutsuka T, et al. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin. Pharmacokinet. 2003;42:1089–1105.10.2165/00003088-200342130-00002
   PubMed Web of Science ®Google Scholar
• Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Controlled Release. 2001;74:47–61.10.1016/S0168-3659(01)00309-1
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Controlled Release. 2000;65:271–284.10.1016/S0168-3659(99)00248-5
   PubMed Web of Science ®Google Scholar
• Puri A, Loomis K, Smith B, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit. Rev. Ther. Drug Carrier Syst. 2009;26:523–580.10.1615/CritRevTherDrugCarrierSyst.v26.i6
   PubMed Web of Science ®Google Scholar
• Shcharbina N, Shcharbin D, Bryszewska M. Nanomaterials in stroke treatment: perspectives. Stroke. 2013;44:2351–2355.10.1161/STROKEAHA.113.001298
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Banerjee S, Padhye S, et al. Parenterally administrable nano-micelles of 3,4-difluorobenzylidene curcumin for treating pancreatic cancer. Colloids Surf. B Biointerfaces. 2015;132:138–145.10.1016/j.colsurfb.2015.05.007
   PubMed Web of Science ®Google Scholar
• Etrych T, Chytil P, Mrkvan T, et al. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting. J. Controlled Release. 2008;132:184–192.10.1016/j.jconrel.2008.04.017
   PubMed Web of Science ®Google Scholar
• Etrych T, Strohalm J, Chytil P, et al. Biodegradable star HPMA polymer conjugates of doxorubicin for passive tumor targeting. Eur. J. Pharm. Sci. 2011;42:527–539.10.1016/j.ejps.2011.03.001
   PubMed Web of Science ®Google Scholar
• She W, Li N, Luo K, et al. Dendronized heparin−doxorubicin conjugate based nanoparticle as pH-responsive drug delivery system for cancer therapy. Biomaterials. 2013;34:2252–2264.10.1016/j.biomaterials.2012.12.017
   PubMed Web of Science ®Google Scholar
• Kaminskas LM, Boyd BJ, Porter CJH. Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. Nanomedicine. 2011;6:1063–1084.10.2217/nnm.11.67
   PubMed Web of Science ®Google Scholar
• Basile L, Pignatello R, Passirani C. Active targeting strategies for anticancer drug nanocarriers. Curr. Drug Delivery. 2012;9:255–268.10.2174/156720112800389089
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of atp-dependent transporters. Nat. Rev. Cancer. 2002;2:48–58.10.1038/nrc706
   PubMed Web of Science ®Google Scholar
• Jain RK. Barriers to drug delivery in solid tumors. Sci. Am. 1994;271:58–65.10.1038/scientificamerican0794-58
   PubMed Web of Science ®Google Scholar
• Shen M, Huang Y, Han L, et al. Multifunctional drug delivery system for targeting tumor and its acidic microenvironment. J. Controlled Release. 2012;161:884–892.10.1016/j.jconrel.2012.05.013
   PubMed Web of Science ®Google Scholar
• Li Q, Xu W. Novel anticancer targets and drug discovery in post genomic age. Curr. Med. Chem. Anticancer Agents. 2005;5:53–63.10.2174/1568011053352631
   PubMedGoogle Scholar
• Zhang L, Zhu S, Qian L, et al. RGD-modified PEG–PAMAM–DOX conjugates: in vitro and in vivo studies for glioma. Eur. J. Pharm. Biopharm. 2011;79:232–240.10.1016/j.ejpb.2011.03.025
   PubMed Web of Science ®Google Scholar
• Gupta U, Dwivedi SKD, Bid HK, et al. Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells. Int. J. Pharm. 2010;393:185–196.
   PubMed Web of Science ®Google Scholar
• Lockman PR, Oyewumi MO, Koziara JM, et al. Brain uptake of thiamine-coated nanoparticles. J. Controlled Release. 2003;93:271–282.10.1016/j.jconrel.2003.08.006
   PubMed Web of Science ®Google Scholar
• Ulbrich K, Knobloch T, Kreuter J. Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J. Drug Target. 2011;19:125–132.10.3109/10611861003734001
   PubMed Web of Science ®Google Scholar
• Huang R, Ke W, Liu Y, et al. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. Biomaterials. 2008;29:238–246.10.1016/j.biomaterials.2007.09.024
   PubMed Web of Science ®Google Scholar
• Pettit MW, Griffiths P, Ferruti P, et al. Poly(amidoamine) polymers: soluble linear amphiphilic drug-delivery systems for genes, proteins and oligonucleotides. Ther. Delivery. 2011;2:907–917.10.4155/tde.11.55
   PubMedGoogle Scholar
• Qin W, Yang K, Tang H, et al. Improved GFP gene transfection mediated by polyamidoamine dendrimer-functionalized multi-walled carbon nanotubes with high biocompatibility. Colloids Surf. B. 2011;84:206–213.10.1016/j.colsurfb.2011.01.001
   PubMed Web of Science ®Google Scholar
• Patri AK, Kukowskalatallo JF, Bakerjr JR. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv. Drug Delivery Rev. 2005;57:2203–2214.10.1016/j.addr.2005.09.014
   PubMed Web of Science ®Google Scholar
• McCarthy TD, Karellas P, Henderson SA, et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol. Pharm. 2:312–318.
   PubMed Web of Science ®Google Scholar
• Sk UH, Dixit D, Sen E. Comparative study of microtubule inhibitors – estramustine and natural podophyllotoxin conjugated PAMAM dendrimer on glioma cell proliferation. Eur. J. Med. Chem. 2013;68:47–57.10.1016/j.ejmech.2013.07.007
   PubMed Web of Science ®Google Scholar
• Bai CZ, Choi S, Nam K, et al. Arginine modified PAMAM dendrimer for interferon beta gene delivery to malignant glioma. Int. J. Pharm. 2013;445:79–87.10.1016/j.ijpharm.2013.01.057
   PubMed Web of Science ®Google Scholar
• Teow HM, Zhou Z, Najlah M, et al. Delivery of paclitaxel across cellular barriers using a dendrimer-based nanocarrier. Int. J. Pharm. 2013;441:701–711.10.1016/j.ijpharm.2012.10.024
   PubMed Web of Science ®Google Scholar
• He H, Li Y, Jia X-R, et al. PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. Biomaterials. 2011;32:478–487.10.1016/j.biomaterials.2010.09.002
   PubMed Web of Science ®Google Scholar
• Li Y, He H, Jia X, et al. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials. 2012;33:3899–3908.10.1016/j.biomaterials.2012.02.004
   PubMed Web of Science ®Google Scholar
• Li M-H, Choi SK, Thomas TP, et al. Dendrimer-based multivalent methotrexates as dual acting nanoconjugates for cancer cell targeting. Eur. J. Med. Chem. 2012;47:560–572.10.1016/j.ejmech.2011.11.027
   PubMed Web of Science ®Google Scholar
• Yang W, Cheng Y, Xu T, et al. Targeting cancer cells with biotin-dendrimer conjugates. Eur. J. Med. Chem. 2009;44:862–868.10.1016/j.ejmech.2008.04.021
   PubMed Web of Science ®Google Scholar
• Hui H, Xiao-dong F, Zhong-lin C. Thermo- and pH-sensitive dendrimer derivatives with a shell of poly(N,N-dimethylaminoethyl methacrylate) and study of their controlled drug release behavior. Polymer. 2005;46:9514–9522.10.1016/j.polymer.2005.07.034
   Web of Science ®Google Scholar
• Zhao J, Zhang B, Shen S, et al. CREKA peptide-conjugated dendrimer nanoparticles for glioblastoma multiforme delivery. J. Colloid Interface Sci. 2015;450:396–403.10.1016/j.jcis.2015.03.019
   PubMed Web of Science ®Google Scholar
• Zhang F, Mastorakos P, Mishra MK, et al. Uniform brain tumor distribution and tumor associated macrophage targeting of systemically administered dendrimers. Biomaterials. 2015;52:507–516.10.1016/j.biomaterials.2015.02.053
   PubMed Web of Science ®Google Scholar
• Mishra V, Gupta U, Jain NK. Surface-engineered dendrimers: a solution for toxicity issues. J. Biomater. Sci. Polym. Ed. 2009;20:141–166.10.1163/156856208X386246
   PubMed Web of Science ®Google Scholar
• Wang F, Cai X, Su Y, et al. Reducing cytotoxicity while improving anti-cancer drug loading capacity of polypropylenimine dendrimers by surface acetylation. Acta Biomater. 2012;8:4304–4313.10.1016/j.actbio.2012.07.031
   PubMed Web of Science ®Google Scholar
• Sideratou Z, Kontoyianni C, Drossopoulou GI, et al. Synthesis of a folate functionalized PEGylated poly(propylene imine) dendrimer as prospective targeted drug delivery system. Bioorg. Med. Chem. Lett. 2010;20:6513–6517.10.1016/j.bmcl.2010.09.058
   PubMed Web of Science ®Google Scholar
• Gajbhiye V, Jain NK. The treatment of glioblastoma xenografts by surfactant conjugated dendritic nanoconjugates. Biomaterials. 2011;32:6213–6225.10.1016/j.biomaterials.2011.04.057
   PubMed Web of Science ®Google Scholar
• Patel SK, Gajbhiye V, Jain NK. Synthesis, characterization and brain targeting potential of paclitaxel loaded thiamine-PPI nanoconjugates. J. Drug Target. 2012;20:841–849.10.3109/1061186X.2012.719231
   PubMed Web of Science ®Google Scholar
• Somani S, Blatchford DR, Millington O, et al. Transferrin-bearing polypropylenimine dendrimer for targeted gene delivery to the brain. J. Controlled Release. 2014;188:78–86.10.1016/j.jconrel.2014.06.006
   PubMed Web of Science ®Google Scholar
• Al-Jamal KT, Al-Jamal WT, Akerman S, et al. Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth. Proc. Nat. Acad. Sci. 2010;107:3966–3971.10.1073/pnas.0908401107
   PubMed Web of Science ®Google Scholar
• Jain K, Jain NK. Surface engineered dendrimers as antiangiogenic agent and carrier for anticancer drug: dual attack on cancer. J. Nanosci. Nanotechnol. 2014;14:5075–5087.10.1166/jnn.2014.8677
   PubMed Web of Science ®Google Scholar
• Kaminskas LM, Kelly BD, McLeod VM, et al. Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker. J. Controlled Release. 2011;152:241–248.10.1016/j.jconrel.2011.02.005
   PubMed Web of Science ®Google Scholar
• Niidome T, Yamauchi H, Takahashi K, et al. Hydrophobic cavity formed by oligopeptide for doxorubicin delivery based on dendritic poly(L-lysine). J. Biomater. Sci. Polym. Ed. 2014;25:1362–1373.10.1080/09205063.2014.938979
   PubMed Web of Science ®Google Scholar
• Sgouras D, Duncan R. Methods for the evaluation of biocompatibility of soluble synthetic polymers which have potential for biomedical use: 1? Use of the tetrazolium-based colorimetric assay (MTT) as a preliminary screen for evaluation of in vitro cytotoxicity. J. Mater. Sci. Mater. Med. 1990;1:61–68.10.1007/BF00839070
   Web of Science ®Google Scholar
• Neerman MF, Chen H-T, Parrish AR, et al. Reduction of drug toxicity using dendrimers based on melamine. Mol. Pharm. 1:390–393.
   PubMed Web of Science ®Google Scholar
• Jevprasesphant R, Penny J, Jalal R, et al. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int. J. Pharm. 2003;252:263–266.10.1016/S0378-5173(02)00623-3
   PubMed Web of Science ®Google Scholar
• Rupp R, Rosenthal SL, Stanberry LR. VivaGel (SPL7013 Gel): a candidate dendrimer–microbicide for the prevention of HIV and HSV infection. Int. J. Nanomed. 2007;2:561–566.
   PubMed Web of Science ®Google Scholar
• Tyssen D, Henderson SA, Johnson A, et al. Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PLoS One. 2010;5:e12309.10.1371/journal.pone.0012309
   Google Scholar
• DEP™ docetaxel. n.d. [cited 2015 Jun 6]. Available from: http://www.starpharma.com/drug_delivery/dep_docetaxel
   Google Scholar
• Kesharwani P, Banerjee S, Gupta U, et al. PAMAM dendrimers as promising nanocarriers for RNAi therapeutics. Mater. Today. 2015;18:565–572.10.1016/j.mattod.2015.06.003
   Web of Science ®Google Scholar
• Mansuri S, Kesharwani P, Tekade RK, et al. Lyophilized mucoadhesive-dendrimer enclosed matrix tablet for extended oral delivery of albendazole. Eur. J. Pharm. Biopharm. 2015. doi:10.1016/j.ejpb.2015.10.015. [Epub ahead of print]
   PubMedGoogle Scholar
• Cheng Y, Xu Z, Ma M, et al. Dendrimers as drug carriers: applications in different routes of drug administration. J. Pharm. Sci. 2008;97:123–143.10.1002/(ISSN)1520-6017
   PubMed Web of Science ®Google Scholar
• Jain S, Kesharwani P, Tekade RK, et al. One platform comparison of solubilization potential of dendrimer with some solubilizing agents. Drug Dev. Ind. Pharm. 2015;41:722–727.10.3109/03639045.2014.900077
   PubMed Web of Science ®Google Scholar
• Gothwal A, Kesharwani P1, Gupta U, et al. Dendrimers as an effective nanocarrier in cardiovascular disease. Curr. Pharm. Des. 2015;21:4519–4526.10.2174/1381612820666150827094341
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Delivery Rev. 2013;65:36–48.10.1016/j.addr.2012.09.037
   PubMed Web of Science ®Google Scholar
• de Visscher SAHJ, Kaščáková S, de Bruijn HS, et al. Fluorescence localization and kinetics of mTHPC and liposomal formulations of mTHPC in the window-chamber tumor model. Lasers Surg. Med. 2011;43:528–536.10.1002/lsm.v43.6
   PubMed Web of Science ®Google Scholar
• Huang S-L, McPherson DD, MacDonald RC. A method to co-encapsulate gas and drugs in liposomes for ultrasound-controlled drug delivery. Ultrasound Med. Biol. 2008;34:1272–1280.10.1016/j.ultrasmedbio.2008.01.005
   PubMed Web of Science ®Google Scholar
• Matteucci ML, Thrall DE. The role of liposomes in drug delivery and diagnostic imaging: a review. Vet. Radiol. Ultrasound. 2000;41:100–107.10.1111/vru.2000.41.issue-2
   PubMed Web of Science ®Google Scholar
• Jain A, Jain K, Kesharwani P, et al. Low density lipoproteins mediated nanoplatforms for cancer targeting. J. Nanopart. Res. 2013;15:1888. doi:10.1007/s11051-013-1888-7 10.1007/s11051-013-1888-7
   Web of Science ®Google Scholar
• Karchemski F, Zucker D, Barenholz Y, et al. Carbon nanotubes-liposomes conjugate as a platform for drug delivery into cells. J. Controlled Release. 2012;160:339–345.10.1016/j.jconrel.2011.12.037
   PubMed Web of Science ®Google Scholar
• Monteiro-Riviere NA, Nemanich RJ, Inman AO, et al. Multi-walled carbon nanotube interactions with human epidermal keratinocytes. Toxicol. Lett. 2005;155:377–384.10.1016/j.toxlet.2004.11.004
   PubMed Web of Science ®Google Scholar
• Lam C-W, James JT, McCluskey R, et al. Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Toxicol. Sci. 2004;77:126–134.
   PubMed Web of Science ®Google Scholar
• Mishra V, Kesharwani P, JainNK. Functionalized polymeric nanoparticles for delivery of bioactives. Nanobiomedicine. 2014;91–123: Publ M/s Stud Press LLC, USA.
   Google Scholar
• Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006;307:93–102.10.1016/j.ijpharm.2005.10.010
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Banerjee S, Padhye S, et al. Hyaluronic acid engineered nanomicelles loaded with 3,4-difluorobenzylidene curcumin for targeted killing of CD44+ stem-like pancreatic cancer cells. Biomacromolecules. 2015;16:3042–3053.10.1021/acs.biomac.5b00941
   PubMed Web of Science ®Google Scholar
• Amjad MW, Amin MCIM, Katas H, et al. In vivo antitumor activity of folate-conjugated cholic acid-polyethylenimine micelles for the codelivery of doxorubicin and siRNA to colorectal adenocarcinomas. Mol. Pharm. 2015;12:4247–4258.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Yokoyama M, Opanasopit P, et al. What are determining factors for stable drug incorporation into polymeric micelle carriers? Consideration on physical and chemical characters of the micelle inner core. J. Controlled Release. 2007;123:11–18.10.1016/j.jconrel.2007.07.008
   PubMed Web of Science ®Google Scholar
• Jain A, Garg NK, Jain A, et al. A synergistic approach of adapalene-loaded nanostructured lipid carriers, and vitamin C co-administration for treating acne. Drug Dev. Ind. Pharm. 2015:1–9. doi:10.3109/03639045.2015.1104343 [Epub ahead of print].
   PubMedGoogle Scholar
• Jain A, Kesharwani P, Garg NK, et al. Galactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin. Colloids Surf. B Biointerfaces. 2015;134:47–58.10.1016/j.colsurfb.2015.06.027
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur. J. Pharm. Biopharm. 2000;50:161–177.10.1016/S0939-6411(00)00087-4
   PubMed Web of Science ®Google Scholar
• Denora N, Laquintana V, Lopalco A, et al. In vitro targeting and imaging the translocator protein TSPO 18-kDa through G(4)-PAMAM-FITC labeled dendrimer. J. Controlled Release. 2013;172:1111–1125.10.1016/j.jconrel.2013.09.024
   PubMed Web of Science ®Google Scholar
• Biswas S, Deshpande PP, Navarro G, et al. Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. Biomaterials. 2013;34:1289–1301.10.1016/j.biomaterials.2012.10.024
   PubMed Web of Science ®Google Scholar
• Kaminskas LM, Kelly BD, McLeod VM, et al. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers. Mol. Pharm. 6:1190–1204.
   PubMed Web of Science ®Google Scholar
• Kaneshiro TL, Lu Z-R. Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials. 2009;30:5660–5666.10.1016/j.biomaterials.2009.06.026
   PubMed Web of Science ®Google Scholar
• Kuang Y, An S, Guo Y, et al. T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting. Int. J. Pharm. 2013;454:11–20.10.1016/j.ijpharm.2013.07.019
   PubMed Web of Science ®Google Scholar
• Wu G, Yang W, Barth RF, et al. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin. Cancer Res. 2007;13:1260–1268.10.1158/1078-0432.CCR-06-2399
   PubMed Web of Science ®Google Scholar
• Huang S, Li J, Han L, et al. Dual targeting effect of Angiopep-2-modified. DNA-loaded nanoparticles for glioma. Biomaterials. 2011;32:6832–6838.
   Google Scholar
• Choi JS, Nam K, Park J-Y, et al. Enhanced transfection efficiency of PAMAM dendrimer by surface modification with l-arginine. J. Controlled Release. 2004;99:445–456.10.1016/j.jconrel.2004.07.027
   PubMed Web of Science ®Google Scholar
• Kim J-B, Choi JS, Nam K, et al. Enhanced transfection of primary cortical cultures using arginine-grafted PAMAM dendrimer, PAMAM-Arg. J. Controlled Release. 2006;114:110–117.10.1016/j.jconrel.2006.05.011
   PubMed Web of Science ®Google Scholar
• Peng C, Zheng L, Chen Q, et al. PEGylated dendrimer-entrapped gold nanoparticles for in vivo blood pool and tumor imaging by computed tomography. Biomaterials. 2012;33:1107–1119.10.1016/j.biomaterials.2011.10.052
   PubMed Web of Science ®Google Scholar
• Han L, Li J, Huang S, et al. Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1 magnetic resonance imaging contrast agent. Biomaterials. 2011;32:2989–2998.10.1016/j.biomaterials.2011.01.005
   PubMed Web of Science ®Google Scholar
• Koppu S, Oh YJ, Edrada-Ebel R, et al. Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA. J. Controlled Release. 2010;143:215–221.10.1016/j.jconrel.2009.11.015
   PubMed Web of Science ®Google Scholar
• Aldawsari H, Edrada-Ebel R, Blatchford DR, et al. Enhanced gene expression in tumors after intravenous administration of arginine-, lysine- and leucine-bearing polypropylenimine polyplex. Biomaterials. 2011;32:5889–5899.10.1016/j.biomaterials.2011.04.079
   PubMed Web of Science ®Google Scholar
• Shah V, Taratula O, Garbuzenko OB, et al. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin. Cancer Res. 2013;19:6193–6204.10.1158/1078-0432.CCR-13-1536
   PubMed Web of Science ®Google Scholar
• Liu S, Guo Y, Huang R, et al. Gene and doxorubicin co-delivery system for targeting therapy of glioma. Biomaterials. 2012;33:4907–4916.10.1016/j.biomaterials.2012.03.031
   PubMed Web of Science ®Google Scholar